Clinical trials: Renal Carcinoma
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT02178722
- Testing
- MK-3475, INCB024360
- Where
- 24 sites in United States
- Volunteers
- 444 people
- Sponsor
- Incyte Corporation
Clear-cell Metastatic Renal Cell Carcinoma
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy.
- Trial name
- A-PREDICT (NCT01693822)
- Testing
- Axitinib
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
This study is testing a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread to other parts of the body (metastatic clear cell renal cell carcinoma).
- Trial name
- NCT07488572
- Testing
- Yivoximab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Brain and Central Nervous System Tumors, Kidney Cancer
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer.
- Trial name
- NCT01553175
- Testing
- DNA analysis, gene expression analysis, mutation analysis
- Volunteers
- 25 people
- Sponsor
- Children's Oncology Group
Renal Cell Carcinoma
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC.
- Trial name
- NCT00557830
- Testing
- Sorafenib Escalated Dose, Sorafenib Standard Dose
- Where
- 13 sites in United States
- Volunteers
- 12 people
- Sponsor
- Accelerated Community Oncology Research Network
Advanced Renal Cell Carcinoma, Renal Cell Carcinoma
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated…
- Conditions
- Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- ADAPT (NCT01582672)
- Testing
- Standard Treatment, AGS-003
- Where
- 125 sites in United States, Canada and 6 more
- Volunteers
- 462 people
- Sponsor
- Argos Therapeutics
Metastatic Renal Cell Carcinoma (mRCC)
A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor
This is a Norwegian prospective registration, observational study of patients with advanced renal cell cancer on Afinitor treatment after failure of one Tyrosine Kinase Inhibitor (TKI) ( e.g. sunitinib or sorafenib).
- Trial name
- OSAT (NCT01390519)
- Testing
- everolimis
- Where
- 3 sites in Norway
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer
Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic Cancer
Nivolumab is a selective monoclonal antibody that binds to the Programmed cell Death 1 (PD-1) receptor and causes reduced tumor growth. It is currently approved in France in many indications.
- Trial name
- IMEPOCA (NCT05380336)
- Where
- France
- Volunteers
- 40,000 people
- Sponsor
- Nantes University Hospital
Advanced Solid Tumor, Metastatic Solid Tumor
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
- Trial name
- NCT04977453
- Testing
- GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib
- Where
- 13 sites in United States, South Korea
- Volunteers
- 317 people
- Sponsor
- GI Innovation, Inc.
Renal Cell Carcinoma
A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread
A medical review chart study in Japan to describe the treatment patterns and outcomes of patients with kidney cancer that is unable to be removed by surgery or that has spread.
- Trial name
- NCT03161145
- Where
- Japan
- Volunteers
- 297 people
- Sponsor
- Bristol-Myers Squibb
Urinary Bladder Neoplasms, Neoplasm Metastasis
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer.
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
- Trial name
- FORAGER-1 (NCT05614739)
- Testing
- Vepugratinib, Pembrolizumab, enfortumab vedotin
- Where
- 83 sites in United States, Australia and 12 more
- Volunteers
- 677 people
- Sponsor
- Eli Lilly and Company
Diarrhea, Colitis
FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis
The goal of this clinical trial is to determine the outcome of patients with immune checkpoint inhibitor-mediated diarrhea/colitis (IMC) treated with faecal microbiota transplantation (FMT) in a randomised, placebo-controlled…
- Conditions
- Diarrhea, Colitis, Malignant Melanoma, Kidney Cancer
- Trial name
- Immunobiome (NCT06206707)
- Testing
- Faecal Microbiota Transplantation (FMT)
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Carcinoma, Renal Cell, Kidney Neoplasms
Safety and Efficacy of Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1 Stage Renal Carcinoma
Partial nephrectomy(PN) and tumor enucleation(TE) are the two main methods of Nephron-sparing surgery for early renal cell carcinoma.
- Trial name
- NCT05790122
- Where
- China
- Volunteers
- 146 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Kidney Cancer, Renal Cell Carcinoma
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor…
- Conditions
- Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04623502
- Testing
- 13C-Glucose, 13C-Acetate, 13C-Lactate
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Renal Cell Carcinoma
Treatment of Advanced Renal Cell Carcinoma With Quinacrine
The overall response to standard therapies and to the newer antiangiogenesis therapies is not curative, and treatment-associated toxicities may be severe.
- Trial name
- NCT00574483
- Testing
- quinacrine
- Where
- 2 sites in United States
- Sponsor
- Cleveland BioLabs
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Renal Tumors
Federated Learning in Renal Tumor Model
This is a multicenter, retrospective and prospective diagnostic clinical trial evaluating the effectiveness and safety of CascadeDiagnose Renal Tumor CT, an AI-assisted detection system for renal tumors based on contrast-enhanced…
- Trial name
- NCT07841756
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Renal Cell Carcinoma, Ovarian Cancer
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended…
- Conditions
- Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer
- Trial name
- NCT06010875
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Renal Cell Carcinoma
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
- Trial name
- NCT04088500
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.